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Ability to predict response to cardiac resynchronization
therapy (CRT) has been one of the challenges in the treatment
of heart failure (HF). Although CRT has been associated
with significant clinical improvement in large clinical trials
(1–3), approximately 30% of the patients do not experience
clinical improvement (4). Several factors of CRT nonre-
sponse have been implicated, such as inappropriate left
ventricular (LV) lead positioning, the extent and location of
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scar tissue, lack of LV mechanical dyssynchrony, and
inadequate atria-to-ventricle (AV) or ventricle-to-ventricle
(VV) optimization. Recent trials demonstrating benefit in
patients with New York Heart Association (NYHA) func-
tional class I and II HF (5,6) will likely increase the number
of eligible patients for CRT. However, despite advances in
treatment, technology, and experience, the ratio of nonre-
sponders still remains at approximately one-third (6). With
the expansion of CRT-eligible patients, the absolute num-
ber of nonresponders will likely increase, underlining the
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sponse and therefore improving selection for CRT.
Prediction of response. Several strategies have been devel-
oped to improve response to CRT, including better selec-
tion of patients, optimal LV lead placement, and optimiza-
tion of device programming. The characteristics of patients
likely to respond to CRT are already well-known (Fig. 1),
such as nonischemic dilated cardiomyopathy, wide QRS
(150 ms), left bundle branch block, low burden of myo-
cardial scar, preserved posterolateral wall function, and
placement of LV lead in posterior or lateral position (7). In
this issue of the Journal, Duckett et al. (8) observed that
ptimizing LV lead placement with the rise in maximum
ate of left ventricular pressure (LV-dP/dtmax) was associ-
ated with reduction in left ventricular end-systolic volume
(LVESV), improvements in NYHA functional class, and
quality of life at 6 months. Acute hemodynamic improve-
ment in dP/dtmax with optimal LV lead position has been
escribed before (9–11). Duckett et al. (8) for the first time
xtend these findings to demonstrate the association of
ptimal coronary vein selection guided by dP/dtmax with
reversal of remodeling and clinical response.
The patients enrolled in the study by Duckett et al. (8)
fulfilled the standard guideline criteria for CRT but also had
left bundle branch block, and their mean QRS duration was
160  23 ms. Seventy percent demonstrated an improve-
ent in dP/dtmax during LV pacing; and 77% of these
patients demonstrated a reduction in LVESV. A 10% rise
in dP/dtmax during LV pacing at the optimal site predicted
eduction in LVESV with a 94% sensitivity and 64%
pecificity. This approach is quite sensitive in predicting the
esponders but does not seem to provide incremental sen-
itivity over conventional criteria such as QRS duration. In
he study by Duckett et al. (8), QRS duration of 146 ms
ad a higher (100%), and the echocardiographic measure-
ent of interventricular mechanical delay had a similar
94%) sensitivity to predict response, compared with the
10% rise in dP/dtmax during LV pacing.
Prediction of nonresponse. Despite our ability to recog-
nize patients with high likelihood of response to CRT well,
the major challenge lies in predicting the long-term nonre-
sponse to CRT. In the study by Duckett et al. (8), specificity
or the ability of the increase in LV-dP/dtmax 10% with
RT to detect the nonresponder at 6 months (64%) was not
etter than the specificity of baseline QRS duration 146
s (64%) or interventricular mechanical delay 40 ms
86%). Baseline QRS 150 ms by itself has been reported
o have a higher specificity of 80% in predicting nonre-
ponse to CRT (12). A 11% rise in dP/dt by Duckett et
l. (8), however, increased the specificity to 86%, raising the
ossibility that even a higher cutoff such as 15% rise in
P/dtmax could further enhance the ability to detect the
nonresponder. Interestingly, 26% of the patients who had a
10% rise in dP/dtmax in this study did not have a reduction
in LVESV; thus, by this approach, the false positive rate was
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rate in the historical CRT criteria in the clinical trials (4).
One of the very important findings of Duckett et al. (8) was
that the false negative rate was only 10% (negative predictive
value 90%); thus, if the acute hemodynamic response was
absent, it was unlikely that the patient would respond to
CRT. More importantly, the approach seemed to provide
incremental information on subgroups of patients with
characteristics of borderline benefit from CRT, such as
narrow QRS or ischemic cardiomyopathy. According to
Figure 5 in this study (8), the specificity as well as the
sensitivity in the ischemic cardiomyopathy subgroup was
close to 100%, emphasizing importance of utility in these
patients.
Reversal of remodeling and long-term symptomatic benefit.
The magnitude of symptomatic benefit in CRT trials in
patients with NYHA functional class III and IV HF is
modest and consistent (1–3) with the placebo-subtracted
improvement in NYHA functional capacity seen in 15% to
Figure 1 Proposed Algorithm for Future Studies
A proposed algorithm for future studies to test whether guided left ventricular (LV)
without characteristics likely to benefit from cardiac resynchronization therapy (CR
istics likely to benefit from CRT. 2D  2-dimensional; 3D  3-dimensional; AV  a
ular pressure rise; IVCD  intraventricular conduction defect; LBBB  left bundle bra
VV  ventricle-to-ventricle.30% of the patients (4). In the study by Duckett et al. (8),most patients had an improvement in NYHA functional
class (91%) and quality of life (94%), but only 56% had a
reduction in LVESV. Although reversal of remodeling has
been shown to correlate with clinical outcomes with CRT
(13), as much as 28% of patients have improvement in
symptoms without reversal of remodeling (14). Due to the
absence of a control group, this raises further questions of
whether some of the clinical improvement was attributable
to the placebo effect or nonblinding, whether there were
benefits of CRT independent of reversal of remodeling, or
whether there was a treatment effect other than CRT.
Added procedural risk of optimization of LV lead placement
with dP/dtmax. The LV lead location is an important factor
in achieving response to CRT. Findings of Duckett et al. (8)
and others (9–11) strongly support the use of dP/dtmax to
optimize LV lead placement. This approach unfortunately
might be limited by coronary vein anatomy, lead delivery
and stability, added risk, and extended duration of the
procedure. However, a 3% complication rate of coronary vein
ocalization according to acute hemodynamic response to LV pacing in patients
ld be comparable to a standard implantation approach in patients with character-
-ventricle; CT  computed tomography; dP/dtmax  maximum rate of left ventric-
ck; LVEF  left ventricular ejection fraction; RBBB  right bundle branch block;lead l
T) wou
tria-to
nch blodissection and the average procedure time of 138 38 min in
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this study, 2 coronary sinus veins were present in a
majority (91%) of the patients. In other studies, however,
approximately 50% of patients had only a single vein, and as
many as 20% did not have a feasible vein that reached the
LV free wall (16,17). Thus, dP/dt can be helpful to identify
the best site for the LV lead in patients with feasible
coronary vein anatomy, and the risk of acute hemodynamic
testing might be acceptable in patients without the classical
features of high likelihood of response (Fig. 1).
Future directions. Unfortunately, the major limitation of
the study by Duckett et al. (8) was absence of a control
group. Future studies with a risk-stratified approach as
depicted in Figure 1 will help clarify whether LV lead
localization guided by acute hemodynamic response would
be better, compared with a control group with standard
approaches. In patients with characteristics of high likeli-
hood of benefit from CRT, the added risk of extra testing
with dP/dt might not be warranted. In those without such
characteristics, invasive (9–11) or noninvasive (18) testing
of acute hemodynamic response during CRT implantation
to guide LV lead implantation might be beneficial. Addi-
tionally, pre-procedure noninvasive imaging to identify site
of delayed LV contraction to tailor lead position (19) might
be helpful. Finally, whether a nonresponse to early surrogate
testing will identify the chronic nonresponder to CRT, with
respect to hard clinical end points, remains to be answered.
Without such evidence, it would be difficult to withhold
CRT in patients with the standard indications.
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